Page 58 - Clinical Development News Today

— Multicenter study to investigate safety and efficacy of allogeneic stem cell therapy in cats with refractory feline chronic gingivostomatitis (FCGS) —

Varda, a company founded by former SpaceX employees, is taking pharmaceutical manufacturing all the way to space.

/PRNewswire/ -- DelveInsights Metastatic Castration-Sensitive Prostate Cancer Market Insights report includes a comprehensive understanding of current...

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it received Breakthrough Therapy designation from the U.S. Food and Drug...

A phase 2 study looking into the treatment setanaxib for inherited kidney disease, Alport syndrome, has begun it was announced last week.

A significantly greater improvement in people with depression was achieved after they were given ALT-300, an adjunctive treatment, during a phase 2a study.

To explore Oryzon’s clinical candidate ORY-4001 in ALS The ALS Association to provide 500,000 USD funding MADRID, Spain and BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, announced today the start of a preclinical collaboration with the ALS Association. The Association has awarded Oryzon a 498,690 USD grant th...

An AI-designed antibody against an oncology target can now be delivered following a collaboration between Absci Corporation and AstraZeneca.

/PRNewswire/ -- Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted TAR-200 Breakthrough Therapy Designation (BTD)...

PARIS--(BUSINESS WIRE)--Regulatory News:Orano Med (Orano group subsidiary), a leading innovator in the field of Targeted Alpha Therapies in oncology, is thrilled to announce the appointment of Dr. Volker Wagner MD PhD as its new Chief Medical Officer. Dr. Wagner brings a wealth of experience and expertise to the rol...